<table class=wikitable><tr><th>Antibody</th><th>Brand name</th><th>Approval date</th><th>Type</th><th>Target</th></tr><tr><td>Alemtuzumab</td><td>Campath</td><td>2001</td><td>humanized</td><td>CD52</td></tr><tr><td>Bevacizumab</td><td>Avastin</td><td>2004</td><td>humanized</td><td>vascular endothelial growth factor</td></tr><tr><td>Brentuximab vedotin</td><td>Adcetris</td><td>2011</td><td>chimeric</td><td>CD30</td></tr><tr><td>Cetuximab</td><td>Erbitux</td><td>2004</td><td>chimeric</td><td>epidermal growth factor receptor</td></tr><tr><td>Gemtuzumab ozogamicin</td><td>Mylotarg</td><td>2000</td><td>humanized</td><td>CD33</td></tr><tr><td>Ibritumomab tiuxetan</td><td>Zevalin</td><td>2002</td><td>murine</td><td>CD20</td></tr><tr><td>Panitumumab</td><td>Vectibix</td><td>2006</td><td>human</td><td>epidermal growth factor receptor</td></tr><tr><td>Rituximab</td><td>Rituxan, Mabthera</td><td>1997</td><td>chimeric</td><td>CD20</td></tr><tr><td>Trastuzumab</td><td>Herceptin</td><td>1998</td><td>humanized</td><td>ErbB2</td></tr></table>
